HER2 Positive

16 registered clinical trials studyying HER2 Positive — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Canc NCT07059338	Sun Yat-sen University	Phase 2
Recruiting	Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoad NCT07108127	Peking Union Medical College Hospital	Phase 2
Active Not Recruiting	Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617	SystImmune Inc.	Phase 1
Not Yet Recruiting	Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer NCT06818773	Eastern Hepatobiliary Surgery Hospital	Phase 4
Active Not Recruiting	CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors NCT06254807	Carisma Therapeutics Inc	Phase 1
Unknown	A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) NCT05135715	RemeGen Co., Ltd.	Phase 2
Unknown	SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positiv NCT05218148	Aiping Zhou	Phase 2
Recruiting	A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Ne NCT05035836	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929	Carisma Therapeutics Inc	Phase 1
Unknown	Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer NCT04152057	West China Hospital	Phase 1 / Phase 2
Terminated	A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With NCT02202746	Clovis Oncology, Inc.	Phase 2
Active Not Recruiting	Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 NCT01996267	The Netherlands Cancer Institute	Phase 3
Completed	Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Sc NCT01226316	AstraZeneca	Phase 1
Terminated	Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer NCT01238029	Sponsor GmbH	Phase 1
Completed	Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study NCT00768859	The Netherlands Cancer Institute	Phase 2
Completed	Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer NCT00614978	Jules Bordet Institute	Phase 1